Compare BMM & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMM | PHAT |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Canada | United States |
| Employees | 68 | 371 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.1M | 590.6M |
| IPO Year | N/A | 2019 |
| Metric | BMM | PHAT |
|---|---|---|
| Price | $4.83 | $7.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $11.81 | ★ $20.45 |
| AVG Volume (30 Days) | 410.8K | ★ 1.1M |
| Earning Date | 11-23-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $80.50 |
| Revenue Next Year | N/A | $56.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $3.47 | $6.91 |
| 52 Week High | $8.63 | $18.31 |
| Indicator | BMM | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 37.55 |
| Support Level | $4.81 | $6.91 |
| Resistance Level | $6.08 | $9.74 |
| Average True Range (ATR) | 0.39 | 0.39 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 8.21 | 23.18 |
Blue Moon Metals Inc is a Canadian exploration stage company focused on the exploration and development of mineral resource properties. The company is advancing its Blue Moon polymetallic deposit which contains zinc, gold, silver, and copper. The projects of the company include the Nussir copper-gold-silver property in Norway (the "Nussir Property"), the Blue Moon zinc-copper-gold-silver property in California, USA (the "Blue Moon Property"), the NSG copper-zinc-gold-silver property in Norway (the "NSG Property") the Springer tungsten-molybdenum project in the Nevada, USA (the "Springer Property") and the Apex germanium-gallium-copper project in Utah, USA (the "APEX Property").
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.